as 10-28-2024 4:00pm EST
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Founded: | 1992 | Country: | United States |
Employees: | N/A | City: | SOMERVILLE |
Market Cap: | 93.1M | IPO Year: | 2013 |
Target Price: | $4.63 | AVG Volume (30 days): | 5.1M |
Analyst Decision: | Hold | Number of Analysts: | 11 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.08 | EPS Growth: | N/A |
52 Week Low/High: | $0.45 - $5.53 | Next Earning Date: | 11-08-2024 |
Revenue: | $54,900,000 | Revenue Growth: | 483.79% |
Revenue Growth (this year): | 223.37% | Revenue Growth (next year): | 145.60% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Klima Thomas J | BLUE | See Remarks | Sep 30 '24 | Sell | $0.53 | 1,006 | $528.85 | 170,000 | |
Obenshain Andrew | BLUE | President and CEO | Sep 30 '24 | Sell | $0.53 | 34,780 | $18,269.93 | 375,218 |
BLUE Breaking Stock News: Dive into BLUE Ticker-Specific Updates for Smart Investing
Benzinga
18 days ago
Pharmaceutical Technology
19 days ago
Business Wire
25 days ago
Associated Press Finance
a month ago
Business Wire
a month ago
Benzinga
a month ago
MT Newswires
a month ago
Business Wire
a month ago
The information presented on this page, "BLUE bluebird bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.